MedCity News January 8, 2026
Alveus Therapeutics’ Phase 2-ready lead drug hits the same two targets as Amgen’s MariTide, but with the potential for a dosing advantage. The startup’s pipeline also includes molecules that could compete with drugs in development by Roche and Novo Nordisk.
The race to develop new obesity drugs is playing out with measures of how much and how quickly patients shed weight. Raj Kannan, CEO of startup Alveus Therapeutics, sees the field shaping up as a crowded market with me-too drugs offering incremental differences. He also sees this field focusing on the quantity rather than the quality of weight loss.
Some of the weight patients lose is lean mass, which is basically everything else besides fat. Gastrointestinal side effects continue to...
Today's Sponsors
Today's Sponsor